NICOLA BUCHELI, CARMEN SUSANA

Preferred name

Main Affiliation

Facultad de Ciencias de la Salud Eugenio Espejo

Scopus Author ID

55552960700

Now showing 1 - 7 of 7

Some of the metrics are blocked by your
consent settings
Interleukin-receptor antagonist and tumor necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases
(Wiley, 2021-09-08)
Arturo J Martí-Carvajal
;
Juan Bautista De Sanctis
;
Mark Dayer
;
Cristina Elena Martí-Amarista
;
Eduardo Alegría
Some of the metrics are blocked by your
consent settings
Genetic Variability in Child Growth Among South American Populations: A Perspective Integrating Population Genetics, Growth Standards, and Precision Growth Medicine
(MDPI AG, 2025-09-23)
ZAMBRANO ESPINOSA, ANA KARINA
;
GUEVARA RAMIREZ, ALEXANDRA PATRICIA
;
CADENA ULLAURI, SANTIAGO ANDRE
;
Susana Hidalgo
;
NICOLA BUCHELI, CARMEN SUSANA
Child growth in South America results from a complex interplay of genetic, environmental, and socioeconomic factors. The region’s high ancestral diversity—stemming from Native American, European, and African admixture—shapes growth patterns in ways not fully captured by international standard curves such as World Health Organization (WHO) charts, which are primarily based on European population. This mismatch may cause misclassification, especially among Native American and other underrepresented groups, and reduce the effectiveness of interventions like growth hormone (GH) therapy. Evidence from national surveys, cohort studies, and genetic analyses reveals persistent ethnic and socioeconomic disparities, with Native American children showing higher stunting prevalence even after adjusting for wealth and residence. Differences between WHO and national growth curves further contribute to inconsistent prevalence estimates due to methodological and contextual variants. Regional genomic studies, although limited, have identified population-specific variants, such as FBN1 (E1297G) in Peru, and modulators of GH therapy response, including GHR exon 3 deletion, ACAN, and NPR2, highlighting the role of genetic background, treatment timing, and adherence in height outcomes. These findings underscore the need to move toward precision growth medicine, integrating anthropometry, genetic, environmental, and socioeconomic data to design population-specific growth references, optimize pharmacogenetic approaches, and reduce inequities in pediatric growth care.
Some of the metrics are blocked by your
consent settings
Growth factors for treating diabetic foot ulcers
(Wiley, 2015-10-28)
Arturo J Martí-Carvajal
;
Christian Gluud
;
NICOLA BUCHELI, CARMEN SUSANA
;
SIMANCAS RACINES, DANIEL ALEJANDRO
;
Ludovic Reveiz
Some of the metrics are blocked by your
consent settings
Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases
(Wiley, 2024-09-19)
MARTI CARVAJAL, ARTURO JOSE
;
Mario A Gemmato-Valecillos
;
Diana Monge Martín
;
Mark Dayer
;
Eduardo Alegría-Barrero
Background: Atherosclerotic cardiovascular disease (ACVD) is worsened by chronic inflammatory diseases. Interleukin receptor antagonists (IL-RAs) and tumour necrosis factor-alpha (TNF) inhibitors have been studied to see if they can prevent cardiovascular events. Objectives: The purpose of this study was to assess the clinical benefits and harms of IL-RAs and TNF inhibitors in the primary and secondary prevention of ACVD. Search methods: The Cochrane Heart Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE (including In-Process & Other Non-Indexed Citations), Ovid Embase, EBSCO CINAHL plus, and clinical trial registries for ongoing and unpublished studies were searched in February 2024. The reference lists of relevant studies, reviews, meta-analyses and health technology reports were searched to identify additional studies. No limitations on language, date of publication or study type were set. Selection criteria: RCTs that recruited people with and without pre-existing ACVD, comparing IL-RAs or TNF inhibitors versus placebo or usual care, were selected. The primary outcomes considered were all-cause mortality, myocardial infarction, unstable angina, and adverse events. Data collection and analysis: Two or more review authors, working independently at each step, selected studies, extracted data, assessed the risk of bias and used GRADE to judge the certainty of evidence. Main results: We included 58 RCTs (22,053 participants; 21,308 analysed), comparing medication efficacy with placebo or usual care. Thirty-four trials focused on primary prevention and 24 on secondary prevention. The interventions included IL-1 RAs (anakinra, canakinumab), IL-6 RA (tocilizumab), TNF-inhibitors (etanercept, infliximab) compared with placebo or usual care. The certainty of evidence was low to very low due to biases and imprecision; all trials had a high risk of bias. Primary prevention: IL-1 RAs  The evidence is very uncertain about the effects of the intervention on all-cause mortality(RR 0.33, 95% CI 0.01 to 7.58, 1 trial), myocardial infarction (RR 0.71, 95% CI 0.04 to 12.48, I² = 39%, 2 trials), unstable angina (RR 0.24, 95% CI 0.03 to 2.11, I² = 0%, 2 trials), stroke (RR 2.42, 95% CI 0.12 to 50.15; 1 trial), adverse events (RR 0.85, 95% CI 0.59 to 1.22, I² = 54%, 3 trials), or infection (rate ratio 0.84, 95% 0.55 to 1.29, I² = 0%, 4 trials). Evidence is very uncertain about whether anakinra and cankinumab may reduce heart failure (RR 0.21, 95% CI 0.05 to 0.94, I² = 0%, 3 trials). Peripheral vascular disease (PVD) was not reported as an outcome. IL-6 RAs The evidence is very uncertain about the effects of the intervention on all-cause mortality (RR 0.68, 95% CI 0.12 to 3.74, I² = 30%, 3 trials), myocardial infarction (RR 0.27, 95% CI 0.04 to1.68, I² = 0%, 3 trials), heart failure (RR 1.02, 95% CI 0.11 to 9.63, I² = 0%, 2 trials), PVD (RR 2.94, 95% CI 0.12 to 71.47, 1 trial), stroke (RR 0.34, 95% CI 0.01 to 8.14, 1 trial), or any infection (rate ratio 1.10, 95% CI: 0.88 to 1.37, I2 = 18%, 5 trials). Adverse events may increase (RR 1.13, 95% CI 1.04 to 1.23, I² = 33%, 5 trials). No trial assessed unstable angina. TNF inhibitors The evidence is very uncertain about the effects of the intervention on all-cause mortality (RR 1.78, 95% CI 0.63 to 4.99, I² = 10%, 3 trials), myocardial infarction (RR 2.61, 95% CI 0.11 to 62.26, 1 trial), stroke (RR 0.46, 95% CI 0.08 to 2.80, I² = 0%; 3 trials), heart failure (RR 0.85, 95% CI 0.06 to 12.76, 1 trial). Adverse events may increase (RR 1.13, 95% CI 1.01 to 1.25, I² = 51%, 13 trials). No trial assessed unstable angina or PVD. Secondary prevention: IL-1 RAs The evidence is very uncertain about the effects of the intervention on all-cause mortality (RR 0.94, 95% CI 0.84 to 1.06, I² = 0%, 8 trials), unstable angina (RR 0.88, 95% CI 0.65 to 1.19, I² = 0%, 3 trials), PVD (RR 0.85, 95% CI 0.19 to 3.73, I² = 38%, 3 trials), stroke (RR 0.94, 95% CI 0.74 to 1.2, I² = 0%; 7 trials), heart failure (RR 0.91, 95% 0.5 to 1.65, I² = 0%; 7 trials), or adverse events (RR 0.92, 95% CI 0.78 to 1.09, I² = 3%, 4 trials). There may be little to no difference between the groups in myocardial infarction (RR 0.88, 95% CI 0.0.75 to 1.04, I² = 0%, 6 trials). IL6-RAs The evidence is very uncertain about the effects of the intervention on all-cause mortality (RR 1.09, 95% CI 0.61 to 1.96, I² = 0%, 2 trials), myocardial infarction (RR 0.46, 95% CI 0.07 to 3.04, I² = 45%, 3 trials), unstable angina (RR 0.33, 95% CI 0.01 to 8.02, 1 trial), stroke (RR 1.03, 95% CI 0.07 to 16.25, 1 trial), adverse events (RR 0.89, 95% CI 0.76 to 1.05, I² = 0%, 2 trials), or any infection (rate ratio 0.66, 95% CI 0.32 to 1.36, I² = 0%, 4 trials). No trial assessed PVD or heart failure. TNF inhibitors The evidence is very uncertain about the effect of the intervention on all-cause mortality (RR 1.16, 95% CI 0.69 to 1.95, I² = 47%, 5 trials), heart failure (RR 0.92, 95% 0.75 to 1.14, I² = 0%, 4 trials), or adverse events (RR 1.15, 95% CI 0.84 to 1.56, I² = 32%, 2 trials). No trial assessed myocardial infarction, unstable angina, PVD or stroke. Adverse events may be underestimated and benefits inflated due to inadequate reporting. Authors' conclusions: This Cochrane review assessed the benefits and harms of using interleukin-receptor antagonists and tumour necrosis factor inhibitors for primary and secondary prevention of atherosclerotic diseases compared with placebo or usual care. However, the evidence for the predetermined outcomes was deemed low or very low certainty, so there is still a need to determine whether these interventions provide clinical benefits or cause harm from this perspective. In summary, the different biases and imprecision in the included studies limit their external validity and represent a limitation to determining the effectiveness of the intervention for both primary and secondary prevention of ACVD.
Some of the metrics are blocked by your
consent settings
Liver support systems for adults with acute liver failure
(Wiley, 2022-07-28)
MARTI CARVAJAL, ARTURO JOSE
;
Christian Gluud
;
Lise Lotte Gluud
;
Chavdar S Pavlov
;
Ezequiel Mauro
Some of the metrics are blocked by your
consent settings
Liver support systems for adults with acute-on-chronic liver failure
(Wiley, 2022-11-22)
MARTI CARVAJAL, ARTURO JOSE
;
Christian Gluud
;
Lise Lotte Gluud
;
Chavdar S Pavlov
;
Ezequiel Mauro
Some of the metrics are blocked by your
consent settings
Nutritional Status Assessment of Newborns: Comparison of the CAN Score (Metcoff Methodology), Growth Curves, Anthropometry, and Plicometry
(MDPI AG, 2025-05-12)
Maria L. Felix
;
Carmen Basantes
;
Susana Nicola
;
Susana Hidalgo
;
Patricia Guevara-Ramírez
Fetal malnutrition, characterized by inadequate fat and muscle accretion during intrauterine development, has been linked to adverse outcomes, ranging from neonatal complications to long-term developmental and metabolic disorders. Traditionally, growth curves and birth weight have guided the assessment of newborns’ nutritional status; however, these measures often do not accurately reflect changes in body composition. This review compares several evaluation methods—CAN score (Metcoff methodology), body mass index (BMI), Ponderal Index (PI), McLaren Index, mid–upper arm circumference (MUAC), and plicometry—to provide suggestions on selecting the most appropriate approach, depending on the healthcare setting and population needs. Findings from multiple international studies indicate that the CAN score and BMI are among the most accurate tools, offering better sensitivity and specificity than traditional anthropometric indicators. The CAN score, based on a clinical observation of fat deposits, skin texture, and muscle tone, has been widely used in Latin America and remains a practical and cost-effective option. Nonetheless, recent research suggests that BMI, mainly when used alongside the PI, may outperform the CAN score in certain contexts. Considering the complexity of fetal nutritional assessments, integrating multiple methods enhances the diagnostic accuracy. Early identification of malnourished newborns is essential for timely intervention and improved long-term outcomes. Standardizing these diagnostic tools globally could advance efforts to reduce neonatal morbidity and mortality by 2030.

NICOLA BUCHELI, CARMEN SUSANA

Filters

Settings

Sort By

Results per page